Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has corrected its total acquisition amount to KRW 758.9B following a reduction in the 2nd tranche payment (from USD 86.3M to USD 70.3M) and the finalization of the payment date (May 13, 2026) for its U.S. subsidiary, Celltrion USA, Inc.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Decision on Acquisition of Shares and Capital Securities of Other Corporation (Correction)
- Original Disclosure Date: December 11, 2025 (Correction Filing Date: May 8, 2026 / DART Filing Date: May 11, 2026)
- Reason for Correction: Adjustment of the 2nd capital increase amount and finalization of the payment date
- Target Entity (Issuing Company): Celltrion USA, Inc. (U.S., 100% owned subsidiary of Celltrion)
- Key Corrected Details:
- Total Acquisition Amount: (Before) KRW 782,399,840,000 → (After) KRW 758,873,440,000 (KRW 758.9B / USD 516.1M based on initial FX rate USD/KRW 1,470.40)
- Ratio to Equity: (Before) 4.45% → (After) 4.32%
- Ratio to Total Assets: (Before) 3.72% → (After) 3.60%
- Tranche Breakdown (Total USD 516.1M):
- 1st Tranche: USD 445,800,000 (Completed, Scheduled Date: December 18, 2025)
- 2nd Tranche: (Before) USD 86,300,000 (Within 2026) → (After) USD 70,300,000 (May 13, 2026)
- Purpose of Acquisition: Funding for subsidiary’s acquisition of shares in another entity (U.S. API production facility) and operational capital
- Acquisition Method: Participation in Rights Offering (Cash acquisition, 100 new shares plus capital contribution without share issuance)
- Post-Acquisition Shareholding: 100% (3,150 shares total)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of 2nd Tranche Payment Completion and Subsidiary Financial Reporting
This corrected disclosure specifies the final amount and date (May 13, 2026) for the second capital contribution to Celltrion USA, Inc., making it important to confirm whether the funds are successfully remitted on schedule. Verifying the actual completion of the capital injection and the subsequent acquisition of the U.S. API manufacturing asset is essential to understand the full execution of the corporate action and its financial impact. Fund execution details and updated subsidiary holdings can be verified under the ‘Status of Investments in Other Corporations’ and ‘Notes to Consolidated Financial Statements’ in upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
